Preclinical Alzheimer'S Disease

Preclinical Alzheimer's disease represents the phase where the brain undergoes changes associated with Alzheimer's, such as the formation of amyloid plaques and tau tangles, well before any symptoms are evident. During this period, individuals typically do not exhibit noticeable cognitive decline, although minor alterations in memory or thinking may occur. Identifying preclinical Alzheimer's often involves advanced biomarker tests, including PET scans and cerebrospinal fluid analysis, to detect these early pathological changes. Recognizing this stage is essential for the development of interventions aimed at delaying or preventing the onset of symptomatic Alzheimer's. Early identification enables proactive measures, such as lifestyle modifications and participation in clinical trials, offering a proactive approach to managing and potentially altering the disease's trajectory.